内科理论与实践 ›› 2026, Vol. 21 ›› Issue (02): 138-144.doi: 10.16138/j.1673-6087.2026.02.06
赵凌云1,2,*(
), 赵安琪1,*, 杨玲1, 查晴1, 张煜3, 陆真4, 杨克5, 刘艳1(
)
收稿日期:2025-09-17
修回日期:2025-10-15
出版日期:2026-04-25
发布日期:2026-06-15
通讯作者:
刘 艳 E-mail:liuyan_ivy@126.com
作者简介:作者贡献/Authors’ Contributions赵凌云负责研究概念与设计、数据获取及统计分析、论文撰写与修改等;赵安琪、杨玲和张煜负责部分数据统计分析;查晴和陆真负责部分数据获取及统筹;杨克负责课题设计、质量控制、统计分析指导及论文修订;刘艳负责总体把关及关键性修改与最终定稿。全体作者均审阅并通过最终稿。基金资助:
ZHAO Lingyun1,2,*(
), ZHAO Anqi1,*, YANG Ling1, ZHA Qing1, ZHANG Yu3, LU Zhen4, YANG Ke5, LIU Yan1(
)
Received:2025-09-17
Revised:2025-10-15
Online:2026-04-25
Published:2026-06-15
摘要:
目的:探讨社区老年人群单核细胞/高密度脂蛋白胆固醇比值(monocyte to high-density lipoprotein cholesterol ratio,MHR)、甘油三酯-葡萄糖(triglyceride-glucose,TyG)指数与慢性肾脏病(chronic kidney disease, CKD)之间的相关性,并评估基于MHR、TyG指数联合尿酸、体质量指数(body mass index,BMI)及年龄构建的多元联合预测模型对老年CKD的预测价值。方法:收集2022年上海市浦东新区陆家嘴社区1 653例老年人群的临床资料及外周血检测数据,根据估算肾小球滤过率(estimated glomerular filtration rate,eGFR)将研究对象分为非CKD组[eGFR ≥ 60 mL/(min·1.73 m2)]和CKD组[eGFR< 60 mL/(min·1.73 m2)]。分析MHR-TyG联合预测模型对老年CKD的预测效能。结果:Logistic回归分析显示,年龄、BMI、尿酸、MHR及TyG指数均为CKD的独立危险因素(均P<0.05)。限制性立方样条(restricted cubic spline,RCS)曲线及中介效应分析表明,MHR与CKD的发病风险呈显著的非线性正相关(总体关联性检验P<0.001, 非线性检验P=0.016)。当MHR>0.3时,CKD的发病风险显著上升。MHR在BMI与CKD关系中的中介效应占比为23.88%,在年龄与CKD关系中为4.77%。受试者操作特征(receiver operating characteristic,ROC)曲线分析显示,MHR-TyG联合预测模型的曲线下面积(area under the curve, AUC)为0.826(95% CI: 0.793~0.859,P<0.001),灵敏度为79.1%,特异度为73.4%,预测效能优于任一单一指标。亚组分析提示,MHR在非高危人群(如BMI、尿酸和甘油三酯水平正常者)中仍具有显著的预测价值。结论:年龄、BMI、尿酸、MHR及TyG指数均为CKD的独立危险因素。由MHR-TyG联合年龄、BMI和尿酸构建的CKD风险预测模型具有良好的预测效能,且优于任一单一指标。
赵凌云, 赵安琪, 杨玲, 查晴, 张煜, 陆真, 杨克, 刘艳. MHR-TyG联合多元模型对社区老年人群慢性肾脏病的预测价值研究[J]. 内科理论与实践, 2026, 21(02): 138-144.
ZHAO Lingyun, ZHAO Anqi, YANG Ling, ZHA Qing, ZHANG Yu, LU Zhen, YANG Ke, LIU Yan. Predictive value of the combined MHR-TyG multivariate model for chronic kidney disease in the community-dwelling elderly population[J]. Journal of Internal Medicine Concepts & Practice, 2026, 21(02): 138-144.
表1
2组人群基线资料[M(Q1,Q3)/n(%)/$\bar{x}±s$]
| eGFR≥60 mL/(min·1.73 m2)(n= | eGFR<60 mL/(min·1.73 m2)(n=139) | t/U/χ2 | P | |
| 年龄(岁) | 71 (68, 75) | 79 (72, 85) | −9.11 | <0.001 |
| 男性[n(%)] | 635 (41.9) | 66(47.5) | 1.60 | <0.001 |
| 吸烟[n(%)] | 167 (11.0) | 16 (11.5) | 0.03 | 0.863 |
| 饮酒[n(%)] | 200 (13.2) | 10 (7.2) | 4.15 | 0.042 |
| BMI(kg/m2) | 23.9 (22.0, 26.0) | 24.3 (23.1, 26.6) | −2.96 | 0.003 |
| 收缩压(mmHg) | 140 (128, 152) | 145 (132, 157) | −2.41 | 0.016 |
| 舒张压(mmHg) | 76 (62, 90) | 76 (58, 94) | −0.01 | 0.992 |
| 单核细胞(×109/L) | 0.38 (0.31, 0.46) | 0.41 (0.35, 0.49) | −3.05 | 0.002 |
| 白细胞(×109/L) | 5.95 (5.07, 6.96) | 6.43 (5.25, 7.50) | −2.64 | 0.008 |
| 血小板(×109/L) | 216 (182, 254) | 206 (174, 251) | −1.30 | 0.193 |
| 尿素氮(mmol/L) | 5.1 (4.4, 5.9) | 7.1 (6.2, 8.3) | −13.51 | <0.001 |
| 甘油三酯(mmol/L) | 1.26 (0.92, 1.73) | 1.38 (1.05, 1.85) | −2.16 | 0.031 |
| 肌酐(μmol/L) | 69 (60, 78) | 103 (88, 115) | −17.50 | <0.001 |
| 空腹血糖(mmol/L) | 5.3 (4.9, 6.0) | 5.5 (4.9, 6.6) | −1.70 | 0.088 |
| 低密度脂蛋白胆固醇(mmol/L) | 2.72 (2.21, 3.17) | 2.62 (2.11, 3.25) | −1.30 | 0.193 |
| 高密度脂蛋白胆固醇(mmol/L) | 1.29 (1.13, 1.48) | 1.20 (1.04, 1.37) | −4.64 | <0.001 |
| UA(μmol/L) | 332 (279, 388) | 404 (331, 474) | −8.18 | <0.001 |
| 总胆固醇(mmol/L) | 5.07±1.06 | 4.77±1.20 | 3.21 | 0.002 |
| TyG指数 | 8.62 (8.28, 8.99) | 8.74 (8.35, 9.17) | −2.54 | 0.011 |
| MHR | 0.30 (0.27, 0.38) | 0.35 (0.29, 0.43) | −4.97 | <0.001 |
表2
MHR、TyG指数、UA、BMI、年龄与CKD间二元Logistic回归分析
| 变量 | 模型1 | 模型2 | |||||
| OR(95%CI) | B | P | OR (95%CI) | B | P | ||
| OR:优势比(odds ratio)。模型1 仅纳入BMI、UA、TyG指数及MHR;模型 2 在模型1基础上进一步校正性别与年龄。 | |||||||
| BMI | 1.102 (1.047~1.161) | 0.098 | <0.001 | 1.116 (1.059~1.178) | 0.110 | <0.001 | |
| UA | 1.009 (1.007~1.011) | 0.009 | <0.001 | 1.010 (1.008~1.013) | 0.010 | <0.001 | |
| TyG | 1.492 (1.104~2.016) | 0.400 | 0.009 | 1.833 (1.338~2.513) | 0.606 | <0.001 | |
| MHR | 10.241 (3.584~29.261) | 2.326 | <0.001 | 3.435 (1.061~11.120) | 1.234 | 0.040 | |
| 年龄 | 1.114 (1.090~1.139) | 0.108 | <0.001 | 1.115 (1.090~1.140) | 0.108 | <0.001 | |
| 性别 | 1.252 (0.884~1.773) | 0.224 | 0.207 | 1.258 (0.876~1.806) | 0.230 | 0.213 | |
| [1] |
KDIGO CKD Work Group. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease[J]. Kidney Int Suppl,2013,3(1):1-150.
doi: 10.1038/ki.2013.243 |
| [2] |
GBD Chronic Kidney Disease Collaboration. Global, regional, and national burden of chronic kidney disease, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017[J]. Lancet,2020,395(10225):709-733.
doi: 10.1016/S0140-6736(20)30045-3 |
| [3] | Wang Y, Gu S, Xie Z, et al. Trends and disparities in the burden of chronic kidney disease due to type 2 diabetes in China from 1990 to 2021: a population-based study[J]. J Diabetes,2025,17(4):e70084. |
| [4] |
Ix JH, Katz R, Bansal N, et al. Urine fibrosis markers and risk of allograft failure in kidney transplant recipients: a case-cohort ancillary study of the FAVORIT trial[J]. Am J Kidney Dis,2017,69(3):410-419.
doi: 10.1053/j.ajkd.2016.10.019 |
| [5] |
Øvrehus MA, Zürbig P, Vikse BE, et al. Urinary proteomics in chronic kidney disease: diagnosis and risk of progression beyond albuminuria[J]. Clin Proteomics,2015,12(1):21.
doi: 10.1186/s12014-015-9092-7 |
| [6] | KDIGO CKD Work Group. KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease[J]. Kidney Int,2024,105(4S):S117-S314. |
| [7] | 桑婉玥, 李红建. 单核细胞/高密度脂蛋白胆固醇比值在心血管疾病中的研究进展[J]. 海南医学院学报,2021,27(10):797-800. |
| Sang WY, Li HJ. Research progress of monocyte/high density lipoprotein ratio in cardiovascular diseases[J]. J Hainan Med Univ,2021,27(10):797-800. | |
| [8] |
Jiang M, Yang J, Zou H, et al. Monocyte-to-high-density lipoprotein-cholesterol ratio (MHR) and the risk of all-cause and cardiovascular mortality: a nationwide cohort study in the United States[J]. Lipids Health Dis,2022,21(1):30.
doi: 10.1186/s12944-022-01638-6 |
| [9] |
Sun Y, Ji H, Sun W, et al. Triglyceride glucose (TyG) index: a promising biomarker for diagnosis and treatment of different diseases[J]. Eur J Intern Med,2025,131:3-14.
doi: 10.1016/j.ejim.2024.08.026 |
| [10] | Srinivasan S, Singh P, Kulothungan V, et al. Relationship between triglyceride glucose index, retinopathy and nephropathy in type 2 diabetes[J]. Endocrinol Diabetes Metab,2020,4(1):e00151. |
| [11] |
Lv L, Xiong J, Huang Y, et al. Association between the triglyceride glucose index and all-cause mortality in critically ill patients with acute kidney injury[J]. Kidney Dis (Basel),2023,10(1):69-78.
doi: 10.1159/000535891 |
| [12] |
Kim B, Kim GM, Han K, et al. The triglyceride-glucose index is independently associated with chronic kidney disease in the geriatric population, regardless of obesity and sex[J]. Ann Geriatr Med Res,2023,27(3):258-265.
doi: 10.4235/agmr.23.0096 |
| [13] |
Ahmed N, Dalmasso C, Turner MB, et al. From fat to filter: the effect of adipose tissue-derived signals on kidney function[J]. Nat Rev Nephrol,2025,21(6):417-434.
doi: 10.1038/s41581-025-00950-5 |
| [14] | Yousef A, Fang L, Heidari M, et al. Alterations in mitochondria and cellular senescence in aged sEH null female kidneys[J]. Geroscience,2026,48(2):2707-2725. |
| [15] |
Wang M, Xu W, Shi H. Relationship between the triglyceride-glucose index and chronic kidney disease: a meta-analysis of cohort studies[J]. Horm Metab Res,2025,57(6):385-395.
doi: 10.1055/a-2634-0157 |
| [16] |
Zhang K, Sun W, Lin G, et al. Editorial: the link between metabolic syndrome and chronic kidney disease: focus on diagnosis and therapeutics - volume Ⅱ[J]. Front Endocrinol (Lausanne),2024,15:1442803.
doi: 10.3389/fendo.2024.1442803 |
| [17] |
Xu L, Li D, Song Z, et al. The association between monocyte to high-density lipoprotein cholesterol ratio and chronic kidney disease in a Chinese adult population: a cross-sectional study[J]. Ren Fail,2024,46(1):2331614.
doi: 10.1080/0886022X.2024.2331614 |
| [18] |
Gembillo G, Soraci L, Luciani F, et al. Monocyte-to-HDL ratio (MHR) is associated with overall and renal mortality in community-dwelling older individuals with chronic kidney disease (CKD)[J]. J Transl Med,2026,24(1):300.
doi: 10.1186/s12967-026-07745-7 |
| [19] |
Simental-Mendía LE, Rodríguez-Morán M, Guerrero-Romero F. The product of fasting glucose and triglycerides as surrogate for identifying insulin resistance in apparently healthy subjects[J]. Metab Syndr Relat Disord,2008,6(4):299-304.
doi: 10.1089/met.2008.0034 |
| [20] |
Sánchez-Íñigo L, Navarro-González D, Fernández-Montero A, et al. The TyG index may predict the development of cardiovascular events[J]. Eur J Clin Invest,2016,46(2):189-197.
doi: 10.1111/eci.12583 |
| [21] | Miguel V, Shaw IW, Kramann R. Metabolism at the crossroads of inflammation and fibrosis in chronic kidney disease[J]. Nat Rev Nephrol,2025,21(1):39-56. |
| . 2025,21(1):39-56. | |
| [22] | Li Q, Shao X, Zhou S, et al. Triglyceride-glucose index is significantly associated with the risk of hyperuricemia in patients with diabetic kidney disease[J]. Sci Rep,2022,12(1):19988. |
| [23] | Schanstra JP, Zürbig P, Alkhalaf A, et al. Diagnosis and prediction of CKD progression by assessment of urinary peptides[J]. J Am Soc Nephrol,2015,26(8):1999-2010. |
| [1] | 陈梁国, 邓可武, 刘越, 钟鹏, 白英. 甘油三酯-葡萄糖指数与心房颤动患者发生急性心肌梗死风险的关系[J]. 内科理论与实践, 2025, 20(06): 435-439. |
| [2] | 史曼曼, 马毓华, 郑金鑫, 柯燕容, 王语欣, 刘剑, 王伟铭. 1990年至2021年全球及中国2型糖尿病导致的慢性肾脏病疾病负担及危险因素分析[J]. 诊断学理论与实践, 2025, 24(03): 268-278. |
| [3] | 沈小钰, 沙莎, 殷蕾, 周纬, 茅幼英, 汪张娟, 孙燕, 吴燕. 合并蛋白尿的Ⅰ-Ⅱ期慢性肾脏病儿童动态血压变化的临床研究[J]. 诊断学理论与实践, 2024, 23(05): 531-536. |
| [4] | 罗亚丹, 袁立英, 陆怡德, 王子秋, 王朝晖. 成人患者血尿酸水平调查及相关影响因素分析[J]. 内科理论与实践, 2023, 18(03): 141-145. |
| [5] | 钱莹, 马晓波, 高琛妮, 张春丽, 马骏, 张文, 陈晓农. 慢性肾脏病患者高尿酸血症与高血压的关联分析[J]. 诊断学理论与实践, 2023, 22(02): 160-165. |
| [6] | 钱莹, 马晓波, 高琛妮, 陈孜瑾, 马骏, 俞海瑾, 张文, 陈晓农. 骨折风险评估工具在评估维持性血液透析患者骨折风险中的效能[J]. 诊断学理论与实践, 2023, 22(01): 50-57. |
| [7] | 欧阳彦, 陈孜瑾, 章倩莹, 陈晓农, 谢静远, 任红, 张文, 王伟铭. 慢性肾脏病人群的新型冠状病毒感染临床诊治建议(瑞金医院2023版)[J]. 内科理论与实践, 2023, 18(01): 28-33. |
| [8] | 章晓炎, 徐静, 璩斌. 血清维生素D水平对老年慢性肾脏病患者肾功能的影响[J]. 内科理论与实践, 2022, 17(04): 307-312. |
| [9] | 轩应利, 陈斐虹, 秦丽, 和瑞斌, 庞诗情, 袁江姿. 维生素D与慢性肾脏病患者夜间血压的相关性分析[J]. 内科理论与实践, 2021, 16(04): 246-250. |
| [10] | 范秋灵. 糖尿病肾病和非糖尿病慢性肾脏病患者应用钠-葡萄糖协同转运蛋白2抑制剂:预后评估及相关指南解读[J]. 诊断学理论与实践, 2021, 20(02): 130-137. |
| [11] | 杨聚荣, 林利容. 慢性肾脏病患者妊娠的管理现状及策略[J]. 诊断学理论与实践, 2021, 20(02): 125-129. |
| [12] | 晏焕青, 谢琼虹, 尚达, 戴淑琪, 朱彤莹. 胎球蛋白A对腹膜透析患者冠状动脉钙化发生起始的影响因素分析[J]. 内科理论与实践, 2021, 16(01): 49-52. |
| [13] | 陈晓农, 高琛妮. 肾性贫血的诊治进展[J]. 内科理论与实践, 2021, 16(01): 10-14. |
| [14] | 余舒文, 方正滢, 谢静远. 基因检测在慢性肾脏病诊治中的应用及进展[J]. 诊断学理论与实践, 2020, 19(06): 613-617. |
| [15] | 李贵森. 2019年《中国慢性肾脏病矿物质和骨异常诊治指南》解读[J]. 诊断学理论与实践, 2020, 19(03): 229-231. |
| 阅读次数 | ||||||
|
全文 |
|
|||||
|
摘要 |
|
|||||